ALNY as reported
Alnylam Pharmaceuticals, Inc. reported $3.71B of revenue over the trailing twelve months, +65% on the year before. 10 reported series are charted on this page, each one as filed.
$3.71B
Revenue, trailing twelve months · to Q4 2025 · +65% against the twelve months before
- Net Income
- $272M
Net Income · −198% year on year · trailing twelve months to Q4 2025
- Free Cash Flow
- $465M
Free Cash Flow · −1193% year on year · trailing twelve months to Q4 2025
- Op Margin
- 11%
Op Margin · trailing twelve months to Q4 2025
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $3.71B | +65% | Q4 2025 |
| Net Income | $272M | −198% | Q4 2025 |
| EPS | $1.97 | −191% | Q4 2025 |
| Gross Margin | 82% | n/a | Q4 2025 |
| Op Margin | 11% | n/a | Q4 2025 |
| Net Margin | 4.5% | n/a | Q4 2025 |
| ROE | −9.6% | n/a | Q4 2025 |
| ROA | −1.2% | n/a | Q4 2025 |
| ROIC | 49% | n/a | Q2 2022 · 14 quarters behind |
| Free Cash Flow | $465M | −1193% | Q4 2025 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Alnylam Pharmaceuticals, Inc. (ALNY) - Revenue & ProfitRevenue & ProfitAlnylam Pharmaceuticals, Inc. (ALNY)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Biotechnology
Ranks #57 of 145 by Smart Score